-
1 week ago | 
360dx.com | Kelsy Ketchum
VIENNA – Following last week's announcement by Cepheid and Oxford Nanopore Technologies to partner on automated nanopore sequencing workflows for infectious diseases, the firms provided more details on their upcoming plans on the sidelines the European Society of Clinical Microbiology and Infectious Diseases global congress here this week.
-
1 week ago | 
360dx.com | Kelsy Ketchum
NEW YORK — As President Trump's tariffs go into effect, Abbott executives said on Wednesday that the company is prepared to mitigate the expected impacts in the second half of 2025. On a conference call to discuss the company's first quarter financial results, Abbott CEO Robert Ford said that the firm is "built not just to operate but to succeed in rapidly evolving environments like this" and is "prepared to adeptly manage" the effects of the tariffs.
-
1 week ago | 
360dx.com | Kelsy Ketchum
VIENNA – Irish researchers presented data Saturday at the European Society of Clinical Microbiology and Infectious Diseases global congress validating interleukin-6 as an early detection biomarker for sepsis in children, neonates, and pregnant women.
-
1 week ago | 
360dx.com | Kelsy Ketchum
VIENNA – Irish researchers presented data Saturday at the European Society of Clinical Microbiology and Infectious Diseases global congress validating interleukin-6 as an early detection biomarker for sepsis in children, neonates, and pregnant women.
-
1 week ago | 
360dx.com | Kelsy Ketchum
VIENNA – As metagenomic next-generation sequencing (mNGS) becomes cheaper and easier to use, presenters on Saturday at the European Society of Clinical Microbiology and Infectious Diseases global congress in Vienna, made their case for implementing the method in clinical settings to diagnose infectious diseases.
-
2 weeks ago | 
360dx.com | Kelsy Ketchum
NEW YORK – With new agreements with Laboratory Corporation of America and Quest Diagnostics announced last week, Roche is ramping up commercialization of its sample self-collection devices for human papillomavirus testing. The self-collection solution, which includes two devices, received approval from the US Food and Drug Administration in May for use with the firm's FDA-approved Cobas HPV test.
-
2 weeks ago | 
360dx.com | Kelsy Ketchum
NEW YORK – New data presented at the International Conference on Alzheimer's and Parkinson's Diseases and Related Neurological Disorders in Vienna on Thursday has validated two of Roche's blood-based tests for Alzheimer's disease and moved them closer to commercialization, according to the company.
-
3 weeks ago | 
360dx.com | Kelsy Ketchum
NEW YORK – With the launch of its first product, a rule-out test for pancreatic cysts that can help risk-stratify patients who may have pancreatic cancer, Purdue University spinout Amplified Sciences is aiming to improve early cancer detection. Using ultra-sensitive dyes developed at Cofounder Vincent Jo Davisson's laboratory at Purdue, the company developed its test to "look optically at disparate types of biomarkers" and improve early cancer detection, said CEO Diana Caldwell.
-
3 weeks ago | 
360dx.com | Kelsy Ketchum
NEW YORK – On the back of its 510(k) clearance from the US Food and Drug Administration earlier this month, Danaher subsidiary Beckman Coulter Diagnostics has launched its DxC 500 I analyzer in the US to target low- and medium-throughput laboratories.
-
4 weeks ago | 
360dx.com | Kelsy Ketchum
NEW YORK – After announcing new clinical data last week on the performance of its next-generation pancreatic cancer test PancreaSure, Swedish diagnostic firm Immunovia is preparing to launch the assay in the second half of 2025. The results of the VERIFI study showed the antibody-based ELISA test had 77 percent sensitivity and 88 percent specificity when identifying early-stage pancreatic ductal adenocarcinoma, or PDAC, beating the study's primary endpoint of 65 percent sensitivity.
